

From: [Giordano, Erica](#)
To: [Patel, Manisha \(manisha.patel@novartis.com\)](#)
Cc: ["Riggins, Cindy"; narin.ahmed@novartis.com](#)
Subject: BL 125646 Mycoplasma Validation
Date: Monday, July 24, 2017 8:48:26 AM
Attachments: [image001.png](#)

Good morning,

We have reviewed the Validation Protocol regarding the mycoplasma test to be performed by (b) (4) emailed to us on 7/19/17. Please include (b) (4) in section 9.1 and 9.3 for evaluation of mycoplasma stocks and (b) (4) detection limit. You may use non-cultivable strain of (b) (4) as it was used for (b) (4) method comparability study.

Please confirm receipt of this request.

Thank you,

Erica Giordano

Regulatory Project Manager

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

U.S. Food and Drug Administration

Tel: 240-402-8298

Erica.Giordano@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."